Trump Administration Poised for Significant Tariff Overhaul on Steel, Aluminum, and Pharmaceuticals
International markets are currently responding to emerging headlines regarding potential shifts in U.S. tariff policy, particularly concerning steel, aluminum, and pharmaceuticals. Reports indicate that the Trump administration is contemplating a significant alteration to the existing framework for steel and aluminum duties.
This proposed change would involve shifting the imposition of duties from raw materials to finished products, a move reportedly aimed at simplifying compliance. While the new tariffs on finished goods could be set at 25%, which is lower than the previous 50% tariff on commodity-grade steel and aluminum, this adjustment is broadly expected to effectively raise costs across a wide range of imports.
In addition to the steel and aluminum adjustments, the U.S. is also anticipated to announce new tariffs targeting pharmaceutical companies. These measures would apply to firms that have either not agreed to lower their prices or are currently engaged in price negotiations with the administration. The original tariffs on steel and aluminum were first implemented in 2018.
Get Weekly Market Signals
Join the mailing list for top aggregated insights. No spam, ever.